Occudo Quantitative Strategies LP Fate Therapeutics Inc Transaction History

Occudo Quantitative Strategies LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $284,338 - $745,718	-67,061 Reduced 40.52%	98,452 $561,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $1.25 Million - $3.03 Million	127,062 Added 330.45%	165,513 $1.67 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $1.15 Million - $1.97 Million	-54,536 Reduced 58.65%	38,451 $862,000
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $1.65 Million - $3.94 Million	92,987 New	92,987 $2.3 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $204,036 - $280,705	-3,034 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $197,068 - $320,619	-2,731 Reduced 47.37%	3,034 $250,000
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $219,588 - $581,976	5,765 New	5,765 $524,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.